Kinimmune Inc. has received US$400,000 in funding from the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for its phase I STTR application to advance the preclinical development of KIN-102, an immunostimulant for intratumoral injection that is designed to turn cold tumors hot for synergy with immuno-oncology drugs, such as checkpoint inhibitors.
Small nuclear RNAs (snRNAs) play a crucial role in RNA splicing and cell functioning. The transcription of these RNAs is initiated by small nuclear RNA activation protein complex (SNAPc), and SNAPC4 is the subunit in charge of SNAPc-DNA binding. Previous studies have found that SNAPC4 deficiency led to decreased expression of these RNAs in animal models.
Navrogen Inc. has entered into a cooperative research and development agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate (ADC) NAV-001, under supervision of the NCI.
Vivasc Therapeutics Inc. has initiated work under a second National Institutes of Health (NIH) phase I STTR research grant, in conjunction with Georgetown University.
Virtici LLC has been granted a Small Business Innovation Research (SBIR) award by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to advance VTC-886, a first-in-class small molecule for the prevention of Porphyromonas gingivalis infection.
Intravacc BV has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG), the cause of the sexually transmitted disease gonorrhea.
Aqualung Therapeutics Corp. has been awarded two 3-year National Institutes of Health (NIH) Fast Track awards to support development of ALT-100 (enamptcumab), a humanized monoclonal antibody therapy for the chronic indications of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD).
The U.S. NIH is not generally regarded as a wellspring of concepts and policies in the world of artificial intelligence (AI), but that perception may change soon thanks to the agency’s Bridge2AI program. The agency announced recently that it will drop $130 million into this program over four years in an effort to develop standards for data used in AI research, a key development for device makers seeking to sell products that use these complex algorithms.
RSS
